Home/ Stocks/ KYTX

Kyverna Therapeutics, Inc. Common Stock

KYTX XNAS

$7.64 -0.25 (-3.17%) ▼ 15-min delayed

Open

$7.73

High

$7.95

Low

$7.50

Volume

598.7K

Market Cap

$470.30M

About Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 129 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-36,787,000	$-0.85
Q2 2025	$0	$-42,081,000	$-0.97
Q1 2025	$0	$-44,635,000	$-1.03
FY 2024	$0	$-127,477,000	$-3.33

Earnings & Analyst Ratings

Next Earnings: Mon, May 11, 2026

Calendar →

Related Market News

No specific coverage for KYTX yet. Check out our latest market news or earnings calendar.

Get KYTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Kyverna Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.